Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations

Journal of Clinical Microbiology

Volumn 49, Issue 4, 2011, Pages 1631-1634

  Young, Thomas P ^a,b   Cloherty, Gavin ^a   Fransen, Signe ^c,f   Napolitano, Laura ^c   Swanson, Priscilla ^d   Herman, Christine ^a   Parkin, Neil T ^e   Hackett Jr , John ^d  

^a Abbott Molecular Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d ABBOTT DIAGNOSTICS   (United States)

^e DATA FIRST CONSULTING INC   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BIOASSAY; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ASSAY; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; REAL TIME HUMAN IMMUNODEFICIENCY VIRUS 1 ASSAY; REAL TIME POLYMERASE CHAIN REACTION; VIRUS CULTURE; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION, MISSENSE; PYRROLIDINONES; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953887344     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02253-10     Document Type: Article

References (18)

1. Fransen, S., et al. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446.
2. Fransen, S., et al. 2008. Performance characteristics and validation of the PhenoSense Integrase assay, abstr. H-1214. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. Washington, DC, 25 to 28 October 2008.
3. Giordano, M., T. Kelleher, R. J. Colonno, A. Lazzarin, and K. Squires. 2006. The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. J. Clin. Virol. 35:420-425. (Pubitemid 43324839)
4. Griffith, B. P., and D. R. Mayo. 2006. Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in plasma preparation tubes (PPT). J. Clin. Virol. 35:197-200. (Pubitemid 43053397)
5. Hackett, J., K. C. Luk, and P. Swanson. 2010. Integrase inhibitor resistance- associated mutations have no impact on performance of the Abbott RealTime HIV-1 assay, abstr. 43. Eighth Eur. HIV Drug Resist. Workshop, Sorrento, Italy, 17 to 19 March 2010.
6. Johnson, V. A., et al. 2010. Update of the drug resistance mutations in HIV-1: December 2010. Top. HIV Med. 18:156-163.
7. Lataillade, M., J. Chiarella, and M. J. Kozal. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12:563-570. (Pubitemid 47041156)
8. Metifiot, M., C. Marchand, K. Maddali, and Y. Pommier. 2010. Resistance to integrase inhibitors. Viruses 2:1347-1366.
9. Petropoulos, C. J., et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928. (Pubitemid 30165271)
10. Powderly, W. G. 2010. Integrase inhibitors in the treatment of HIV-1 infection. J. Antimicrob. Chemother. 65:2485-2488.
11. Rhee, S. Y., et al. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31:298-303.
12. Salimnia, H., E. C. Moore, L. R. Crane, R. D. Macarthur, and M. R. Fairfax. 2005. Discordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 monitor (version 1.5) standard and ultrasensitive assays caused by freezing patient plasma in centrifuged Becton-Dickinson Vacutainer brand plasma preparation tubes. J. Clin. Microbiol. 43:4635-4639. (Pubitemid 41298255)
13. Shimura, K., et al. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.
14. Stosor, V., et al. 2005. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin. Infect. Dis. 41:1671-1674. (Pubitemid 41691608)
15. Swanson, P., et al. 2006. Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: Comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA quantitative assays. J. Virol. Methods 137:184-192. (Pubitemid 44419422)
16. Swanson, P., et al. 2006. Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J. Virol. Methods 134:237-243.
17. Tang, N., et al. 2007. A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J. Virol. Methods 146:236-245. (Pubitemid 350026638)
18. Young, T. P., et al. 2010. Integrase inhibitor-resistance-associated mutations (RAM) in clinical specimens: No impact on performance of the Abbott RealTime HIV-1 viral load assay, poster 388, presentation H-927. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.